Davita INC

DaVita Inc. announced a $500 million incremental term loan under its senior secured term loan B facility, maturing in May 2031, to repay its revolving loan facility and for general corporate purposes.

DaVita Inc. announced its first quarter 2026 financial and operating results, reporting consolidated revenues of $3.416 billion and diluted earnings per share of $2.87.

DaVita Inc. announced strong financial and operating results for the fourth quarter and full year ended December 31, 2025, meeting financial targets despite a challenging environment.

DaVita Inc. has entered into an Eighth Amendment to its Credit Agreement, securing new five-year term and revolving credit facilities totaling $3.5 billion to refinance existing debt and extend maturities to November 2030.

DaVita Inc. reported third-quarter 2025 financial results in line with expectations, maintaining full-year guidance and increasing its share repurchase authorization.

DaVita Inc.'s Board of Directors approved an additional $2 billion for its share repurchase program, signaling confidence and commitment to shareholder returns.

DaVita reported Q1 2026 net income of $275 million, driven by steady dialysis patient service revenues and operational efficiencies.

DaVita Inc. reported a significant drop in net income and diluted EPS for the third quarter and year-to-date periods, impacted by increased operating expenses, higher debt costs, and a cybersecurity incident.

DaVita Inc. reports increased total revenues for Q2 2025 and year-to-date, alongside higher debt and ongoing impacts from a recent cybersecurity incident.

DaVita Inc.'s Q1 2025 results reflect the impact of a cybersecurity incident and a severe flu season, alongside strategic financial maneuvers including share repurchases and debt management.

DaVita Inc. reports its third quarter 2024 financial results, showing revenue growth and strategic adjustments amid ongoing economic and industry challenges.

DaVita Inc.'s second quarter results were impacted by the Change Healthcare cyberattack, which caused billing and collection delays, but the company also saw growth in treatment volumes and revenue per treatment.

DaVita Inc. reported a 6.5% increase in total consolidated revenues to $13.643 billion for fiscal year 2025, alongside a slight decrease in operating income and a significant share repurchase program.

DaVita Inc.'s 2024 annual report reveals a company navigating a complex regulatory environment while focusing on integrated kidney care and managing rising costs.

DaVita Inc.'s 2023 annual report highlights a year of navigating market challenges while focusing on strategic growth in integrated kidney care and international operations.

Kathleen Alyce Waters, Chief Legal & Public Affairs Officer at DaVita Inc., sold 15,405 shares of common stock.

DaVita Inc. CEO Javier Rodriguez sold 69,407 shares of common stock over two days in mid-June 2026.

DaVita Inc. director Phyllis Yale reported a gift of 5,038 shares of common stock on May 26, 2026.

Davita Inc. Director Dennis W. Pullin acquired 250 shares of common stock on May 15, 2026, increasing his direct beneficial ownership.

DaVita Inc. Director Gregory J. Moore acquired 250 shares of common stock on May 15, 2026, as reported in a Form 4 filing.

Davita Inc. Director Wendy Lee Schoppert acquired 250 shares of common stock on May 15, 2026, as reported in a Form 4 filing.

DaVita Inc. filed its 2026 Proxy Statement detailing director elections, executive compensation, and 2025 operational performance.

DaVita Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on key corporate matters.

DaVita Inc. has released its notice of the 2025 Annual Meeting of Stockholders and accompanying proxy statement, highlighting the company's performance in 2024 and key governance matters.

DaVita Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on key corporate matters.

DaVita's 2024 proxy statement highlights the company's commitment to a healthier future through integrated kidney care, community impact, and environmental stewardship, alongside board refreshment and stockholder engagement.

Berkshire Hathaway and its affiliates have updated their Schedule 13D filing for DaVita Inc., reflecting a recent share repurchase by DaVita that maintains Berkshire's aggregate beneficial ownership at 45.0% of the outstanding common stock.

The Vanguard Group has reported a 0% beneficial ownership in DaVita Inc. following an internal realignment that disaggregated its reporting.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 5.91% beneficial ownership stake in DaVita Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.0% beneficial ownership stake in DaVita Inc.'s common stock as of March 31, 2025.